BioSpace News Archive

Astellas Pharma Inc. and the Blood and Marrow Transplant Clinical Trials Network presented data from the Phase 3 MORPHO clinical trial which demonstrated favorable results in subgroups of FMS-like tyrosine kinase 3 -internal tandem duplication mutated acute myeloid leukemia patients, including a subgroup of patients with detectable measurable residual disease.

Wugen, Inc. presented data for its two lead programs, WU-CART-007 and WU-NK-101, in separate presentations at the European Hematology Association 2023 Congress, taking place from June 8 – 11, 2023 in Frankfurt, Germany.

Genmab A/S announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab-lenalidomide showed an overall response rate of 98 percent and complete metabolic response of 87 percent in response evaluable patients with relapsed or refractory follicular lymphoma.

BeiGene, a global biotechnology company, announced the presentation of new data from its broad blood cancer portfolio of approved therapies and promising early-stage pipeline products at the 2023 European Hematology Association Hybrid Congress.

HUTCHMED Limited announces that new and updated clinical data related to two novel investigational hematological malignancy therapies, HMPL-306 and amdizalisib, will be presented at the upcoming European Hematology Association Annual Meeting, taking place June 8-11, 2023 in Frankfurt, and the 17th International Conference on Malignant Lymphoma taking place June 13-17, 2023 in Lugano.

ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA ® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Crinetics Pharmaceuticals, Inc. announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois.

Renalytix plc today reported financial results for the fiscal third quarter ended March 31, 2023.

Servier today announced updated data from the Phase 1 trial of TIBSOVO® (ivosidenib tablets) as monotherapy for patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS).

Agiliti Inc. (NYSE: AGTI) (“Agiliti”) today announced that the company will participate at the UBS Healthcare Services Conference, June 27-28, 2023, in Chatham, Mass.